<DOC>
	<DOCNO>NCT01668537</DOCNO>
	<brief_summary>A randomized , double-blind , multicenter Phase II trial compare immunogenicity safety liquid-frozen freeze-dried formulation IMVAMUNE ( MVA-BN® ) smallpox vaccine vaccinia-naïve healthy subject</brief_summary>
	<brief_title>A Phase II Trial Compare Liquid-frozen Freeze-dried Formulation IMVAMUNE ( MVA-BN® ) Smallpox Vaccine Vaccinia-naïve Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<criteria>Inclusion criterion 1 . Male female subject , 1855 year age 2 . The subject read , sign date informed consent form , advise risk benefit trial language understood subject prior performance trial specific procedure sign Health Insurance Portability Accountability Act ( HIPAA ) authorization form 3 . Body Mass Index ( BMI ) ≥ 18.5 &lt; 35 4 . Women childbearing potential ( WOCBP ) must use acceptable method contraception 30 day prior first vaccination , must agree use acceptable method contraception trial , must avoid become pregnant least 28 day last vaccination . A woman consider childbearing potential unless postmenopausal history hysterectomy . ( Acceptable contraception method restrict abstinence , barrier contraceptive , intrauterine contraceptive device license hormonal product ) 5 . WOCBP must negative serum pregnancy test screening ( SCR ) negative urine pregnancy test within 24 hour prior vaccination 6 . White blood cell ≥ 2500/mm3 &lt; ULN 7 . Absolute neutrophil count ( ANC ) within normal limit 8 . Hemoglobin within normal limit 9 . Platelets within normal limit 10 . Adequate renal function define calculated Creatinine Clearance ( CrCl ) &gt; 60 ml/min estimate CockcroftGault equation : For men : ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dl x 72 ) = CrCl ( ml/min ) For woman : multiply result 0.85 = CrCl ( ml/min ) 11 . Adequate hepatic function define : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) absence evidence significant liver disease Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase &lt; 1.5 x ULN 12 . Troponin I &lt; 2 x ULN 13 . Electrocardiogram ( ECG ) without clinically significant finding , e.g . kind atrioventricular intraventricular condition block complete left right bundle branch block , AV node block , QTc PR prolongation , premature atrial contraction atrial arrhythmia , sustain ventricular arrhythmia , two premature ventricular contraction ( PVC ) row , ST elevation consistent ischemia Exclusion criterion 1 . Typical vaccinia scar 2 . Known suspected history smallpox vaccination 3 . History vaccination poxvirusbased vaccine 4 . US Military service 1991 January 2003 5 . Pregnant breastfeed woman 6 . Uncontrolled serious infection , i.e . respond antimicrobial therapy 7 . History serious medical condition , opinion investigator would compromise safety subject would limit subject 's ability complete trial opinion investigator 8 . History active autoimmune disease , person vitiligo thyroid disease take thyroid hormone replacement exclude 9 . Known suspected impairment immunologic function include , limited , clinically significant liver disease , diabetes mellitus , moderate severe kidney impairment 10 . History malignancy , squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . Subjects history skin cancer must vaccinate previous tumor site 11 . History clinical manifestation clinically significant severe hematological , pulmonary , central nervous , cardiovascular gastrointestinal disorder 12 . Clinically significant mental disorder adequately control medical treatment 13 . History coronary heart disease , myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , uncontrolled high blood pressure , heart condition care doctor 14 . History immediate family member ( father , mother , brother , sister ) onset ischemic heart disease age 50 year 15 . Twenty percent great risk develop myocardial infarction coronary death within next 10 year use National Cholesterol Education Program 's Risk Assessment Tool : http : //hin.nhlbi.nih.gov/atpiii/calculator.asp NOTE : This criterion apply subject 20 year age old 16 . Active history chronic alcohol abuse and/or intravenous and/or nasal drug abuse ( within past 6 month ) 17 . Known allergy IMVAMUNE® vaccine constituent , e.g . tris ( hydroxymethyl ) amino methane , include know allergy egg aminoglycoside ( gentamycin ) 18 . History anaphylaxis severe allergic reaction vaccine 19 . Acute disease ( illness without fever ) time enrollment 20 . Body Temperature ≥ 100.4°F ( 38.0°C ) time enrollment 21 . Having receive vaccination plan vaccination live vaccine within 30 day prior trial vaccination 22 . Having receive vaccination plan vaccination kill vaccine within 14 day prior trial vaccination 23 . Chronic systemic administration ( defined 14 day ) &gt; 5 mg prednisone ( equivalent ) /day immunemodifying drug period start three month prior administration vaccine end last physical trial visit ( Visit 5 ) 24 . Post organ transplant subject whether receive chronic immunosuppressive therapy 25 . Administration plan administration immunoglobulin and/or blood product period start three month prior administration vaccine end last physical trial visit ( Visit 5 ) 26 . Use investigational nonregistered drug vaccine trial vaccine within 30 day precede first dose trial vaccine plan administration drug trial period ( day FU call consider last day trial period ) . 27 . Trial personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>